Humacyte (NASDAQ:HUMA - Get Free Report) will likely be announcing its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.
Humacyte Price Performance
HUMA stock remained flat at $3.32 during trading on Monday. The company had a trading volume of 1,605,380 shares, compared to its average volume of 3,141,842. Humacyte has a 12 month low of $2.75 and a 12 month high of $9.97. The business's fifty day moving average price is $3.81 and its 200-day moving average price is $4.60. The stock has a market cap of $417.85 million, a PE ratio of -2.48 and a beta of 1.36.
Analyst Upgrades and Downgrades
HUMA has been the subject of several research reports. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. Finally, Benchmark reissued a "buy" rating on shares of Humacyte in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $13.71.
Read Our Latest Stock Analysis on HUMA
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Recommended Stories
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
